Cardiovascular disease (CVD) has long been a major pain point in the healthcare industry. Conditions such as stroke or IHD (Ischemic Heart Disease) are responsible for a large number of deaths and sequelae worldwide. Therefore, cardiovascular medical devices and their role in heart-related treatments are receiving increasing attention.
Deaths from CVD have continued to rise over the years. A study in the Journal of the American College of Cardiology focused on reviewing the scale of CVD incidence over the past three decades. The results showed that cardiovascular diseases accounted for nearly one-third of all causes of death worldwide in 2019.
These worrying statistics reveal a global need for lower-cost health care programs and treatments to alleviate the multiple pressures associated with CVD risk. A very important part of this process is the development of more advanced and effective medical devices. This will promote substantial growth in the size of the cardiovascular medical device market, which is expected to exceed USD 10 billion by 2027, according to Global Market Insights, Inc.
Minimally invasive treatment has many advantages in the cardiovascular field, and has been favored for many years because of less trauma, less pain, and lower risk of complications than open surgery. In the mid-1990s, minimally invasive treatment was gradually applied in clinic. At that time, the first case of coronary artery and heart valve shunt was performed with the smallest incision.
Thanks to the continuous improvement and development of cardiovascular medical devices, minimally invasive surgery is preferred by more and more doctors and patients. These advanced medical devices are the basis for minimally invasive procedures to become the preferred surgical option, as such procedures are highly dependent on catheters and other specialized medical equipment that enter the body through small incisions for medical intervention, diagnosis and testing.
For example, innovative smart balloon catheter systems are equipped with electronics, sensors and other mechanical components. The design of these devices is still in the process of being adjusted to provide ablation therapy, blood flow data, blood data and electrical stimulation in one device.
In September 2020, the balloon catheter system was designed by a research team from Northwestern University and George Washington University. The system is equipped with a flexible, scalable electrode actuator and sensor matrix as well as pressure and temperature sensors. They are often used in minimally invasive ablation or surgery to treat conditions such as cardiac arrhythmias.
The most common symptoms of COVID-19 are a flu-like dry cough, fever and body aches. While initial reports focused on the disease's impact on the respiratory tract, more recent studies have begun to note that 10–20% of hospitalized patients with COVID-19 develop various heart-related complications, especially atrial fibrillation.
A study by researchers at the University of Pennsylvania showed that the probability of severe arrhythmia in patients with new crowns entering the ICU increased by 10 times, and atrial fibrillation accounted for almost 19% to 21% of all new crown cases.
This fully demonstrates that cardiovascular medical devices have become increasingly important as the main treatment solution for heart-related diseases that emerged during the epidemic. Large players such as Medtronic have struggled to meet the demand for advanced cardiovascular devices. Last month, the company announced the completion of a major pipeline in its pulsed AF AFib treatment trial.
The Investigational Device Exemption (IDE) trial was designed to examine the PulseSelect PFA (Pulse Field Ablation) device that uses pulsed electric fields to treat atrial fibrillation. Cardiologists at The Ohio State University Wexner Medical Center performed the first surgery using the system in the United States in February 2021, and 13 more patients around the world have since been successfully operated on.
Preliminary results of trial Pulse AF study presented at Heart Rhythm Society 2020 Science, with additional evidence presented at an AF symposium earlier this year showing 100% acute response rate, with no device or procedure seen in experimental patients treated with PulseSelect Related questions.
Over the years, with the increasing burden of cardiovascular diseases on the global medical care, the application of advanced treatment technologies will increase substantially, and the cardiovascular device industry will usher in rapid and profitable growth in the future.
Cardiac ablation devices accounted for nearly 72% of the cardiovascular device market in 2020, and GMI expects its growth to accelerate in the future. Rising incidence of atrial fibrillation is the main reason for the growing popularity of such devices. These products address the growing demand for technological innovations in minimally invasive ablation and cardiac ablation devices.
The significant enhancement of the cardiovascular medical devices market relies on a key factor - the risk of CVD and related health issues is now gaining wider attention. This is because the Internet, private hospital heart programs, and public outreach programs by government agencies such as the CDC have increased public health awareness. Consumers are becoming alert to heart disease symptoms and need early diagnosis and access to treatment. The rapid expansion of the elderly population will undoubtedly increase the potential of the medical device field.